Stem cell therapies without tears
By Editorial,
The New Scientist
| 06. 15. 2007
Expect to hear a familiar refrain over the coming days: "There's no need for embryonic stem cells." It is the likely response of those who oppose any interference with human embryos to the exciting news that adult mouse cells can be reprogrammed to an embryonic state by boosting the activity of just four critical genes (see "From adult to embryo").
There are good reasons to question the campaigners' claims. The trick has yet to be achieved in human cells. Even if that can be done, it will still be necessary to show that the reprogrammed cells have the same ability as embryonic cells to develop into different tissues. But let's assume that all these issues can one day be resolved. Would the need for cells isolated from embryos disappear?
The eventual goal of the latest work is to derive stem cell lines genetically matched to patients, from which to grow replacement cells and tissues. Transferring the nucleus of an adult cell into an egg can send it back to an embryonic state, but how such cloning works remains mysterious. Reprogramming...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...